Ultragenyx Pharmaceutical Stock Quote 0LIF - Stock Price, News, Charts, Message Board, Trades

Unlock more advanced trading tools

Join ADVFN today

Current Price

64.79

Bid

0.00

Ask

0.00

Volume

0.00

0.00 Day's Range 0.00

64.79 52 Week Range 64.79

Market Cap

3.601B

Previous Close

64.79

Open

Last Trade

(O)

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

263

Shares Outstanding

82,114,000

Dividend Yield

PE Ratio

-5.94

Earnings Per Share (EPS)

-7.39

Revenue

434.25M

Net Profit

-606.64M

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.ultragenyx.com

Headquarters

Wilmington, Delaware, USA

Founded

1970

Ultragenyx Pharmaceutical Inc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker 0LIF. The last closing price for Ultragenyx Pharmaceutical was $64.79. Over the last year, Ultragenyx Pharmaceutical shares have traded in a share price range of $ 64.79 to $ 64.79.

Ultragenyx Pharmaceutical currently has 82,114,000 shares outstanding. The market capitalization of Ultragenyx Pharmaceutical is $3.60 billion. Ultragenyx Pharmaceutical has a price to earnings ratio (PE ratio) of -5.94.

Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)

Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia...

Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)

Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH) For the...

Ultragenyx lancia in Italia Evkeeza® (evinacumab concentrato in soluzione per infusione) per il trattamento dell’ipercolesterolemia familiare omozigote (HoFH)

Ultragenyx lancia in Italia Evkeeza® (evinacumab concentrato in soluzione per infusione) per il trattamento dell’ipercolesterolemia familiare omozigote (HoFH) Evkeeza è un farmaco, primo nel...

Zur Behandlung der homozygoten familiären Hypercholesterinämie (HoFH): Ultragenyx führt Evkeeza® (Evinacumab) in Deutschland ein

Zur Behandlung der homozygoten familiären Hypercholesterinämie (HoFH): Ultragenyx führt Evkeeza® (Evinacumab) in Deutschland ein Evkeeza® ist das erste von der U.S. Food and Drug...

Period	Open	High	Low	Avg. Daily Vol	VWAP
1	64.79	64.79	64.79	229	64.79	DE
4	64.79	64.79	64.79	280	64.79	DE
12	64.79	64.79	64.79	263	64.79	DE
26	64.79	64.79	64.79	268	64.79	DE
52	64.79	64.79	64.79	2101	64.79	DE
156	64.79	64.79	64.79	1568	64.79	DE
260	64.79	64.79	64.79	1336	64.79	DE

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
TVGNTevogen Bio Holdings Inc	$ 1.57 (84.71%)	3.35M
PEGYPineapple Energy Inc	$ 0.0858 (65.32%)	41.39M
FRGTFreight Technologies Inc	$ 1.29 (41.18%)	5.3M
BIAFbioAffinity Technologies Inc	$ 3.16 (31.12%)	28
GGLLDirexion Daily GOOGL Bull 2X ETF	$ 44.60 (23.82%)	7.32k
ZENVZenvia Inc	$ 1.67 (-24.09%)	5
AHGAkso Health Group	$ 0.60 (-22.08%)	10
VINCVincerx Inc	$ 0.7099 (-20.83%)	142.02k
ANLAdlai Nortye Ltd	$ 10.80 (-19.76%)	2
NSYSNortech Systems Inc	$ 14.00 (-19.08%)	2
PEGYPineapple Energy Inc	$ 0.0858 (65.32%)	41.39M
FRGTFreight Technologies Inc	$ 1.29 (41.18%)	5.3M
IVPInspire Veterinary Partners Inc	$ 0.044 (15.49%)	4.1M
KTRAKintara Therapeutics Inc	$ 0.1879 (18.92%)	3.81M
TVGNTevogen Bio Holdings Inc	$ 1.57 (84.71%)	3.35M